128 Spring Street
121 Bio is a Cambridge-based biopharmaceutical start-up company that is developing a unique portfolio of antibody-based solutions for academic and commercial research laboratories. These innovative products will be based on 121 Bio’s core technology platform comprising proprietary approaches to enzymatic conjugation and single-domain antibody (sdAb) development.121 Bio’s methodology can produce products that provide powerful new capabilities beyond those of currently available techniques and reagents. The goal is to create a company that markets a broad range of products used by leading academic and industry laboratories worldwide, to push the frontiers of biology research and biopharmaceutical research. The company will be based upon rigorous science to validate its products, respected publications to support them, and a culture of excellence and integrity to create a brand this is admired and respected for its quality. It will also develop an environment that is regarded by its employees as a rewarding and fun place to work.
Founder: Hidde L. Ploegh, Ph.D.
Founder and CEO: James R. Gorman, M.D., Ph.D